Clinical stage I testis tumors

The medical oncologist's view

S. D. Williams, Lawrence Einhorn

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

We believe that 'standard' therapy for clinical stage I nonseminomatous testes germ cell tumors (NSGCT) patients continues to be extended bilateral retroperitoneal lymphadenectomy including suprahilar dissection (RPLND). This approach yields cure rates unparalleled in cancer treatment, with negligible treatment mortality and the avoidance of systemic therapy in most patients. Pathologic stage II patients are identified and managed accordingly, with RPLND being potentially curative in these patients. Excluding reproductive function, long-term complications are nearly zero after RPLND. Sterility is a problem but it has been overemphasized and may be reduced by relatively minor operative modification. Option 2 (radiation), we believe, might be reasonable for the rare patient who has unacceptably high operative risk, but long-term complications and a possible inferior therapeutic result make it much less desirable. Option 3 (chemotherapy only) exposes too many patients to systemic therapy and, we believe, has an unacceptable morbidity and mortality compared to option 1. Option 4 (observation) has for us a great deal of appeal for obvious reasons. However, its success is unknown in terms of likelihood of cure. It is not 'standard' therapy and should be offered only in the context of a prospective clinical trial, several of which are currently in progress. Clearly, better staging techniques would be highly desirable. Ultimately, we hope option 4 will succeed option I as preferred management, but that time has not yet arrived. Finally, we believe that success in the management of these patients is contingent upon the availability of experienced physicians of numerous disciplines. All patients should be treated by such individuals, and the rarity of this disease makes such referrals realistic.

Original languageEnglish
Pages (from-to)15-18
Number of pages4
JournalCancer Treatment Reports
Volume66
Issue number1
StatePublished - 1982

Fingerprint

Testis
Neoplasms
Lymph Node Excision
Dissection
Therapeutics
Time Management
Mortality
Oncologists
Infertility
Referral and Consultation
Observation
Clinical Trials
Radiation
Morbidity
Physicians
Drug Therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Clinical stage I testis tumors : The medical oncologist's view. / Williams, S. D.; Einhorn, Lawrence.

In: Cancer Treatment Reports, Vol. 66, No. 1, 1982, p. 15-18.

Research output: Contribution to journalArticle

@article{6ac16a3e46c54fe39b698e268dba35d9,
title = "Clinical stage I testis tumors: The medical oncologist's view",
abstract = "We believe that 'standard' therapy for clinical stage I nonseminomatous testes germ cell tumors (NSGCT) patients continues to be extended bilateral retroperitoneal lymphadenectomy including suprahilar dissection (RPLND). This approach yields cure rates unparalleled in cancer treatment, with negligible treatment mortality and the avoidance of systemic therapy in most patients. Pathologic stage II patients are identified and managed accordingly, with RPLND being potentially curative in these patients. Excluding reproductive function, long-term complications are nearly zero after RPLND. Sterility is a problem but it has been overemphasized and may be reduced by relatively minor operative modification. Option 2 (radiation), we believe, might be reasonable for the rare patient who has unacceptably high operative risk, but long-term complications and a possible inferior therapeutic result make it much less desirable. Option 3 (chemotherapy only) exposes too many patients to systemic therapy and, we believe, has an unacceptable morbidity and mortality compared to option 1. Option 4 (observation) has for us a great deal of appeal for obvious reasons. However, its success is unknown in terms of likelihood of cure. It is not 'standard' therapy and should be offered only in the context of a prospective clinical trial, several of which are currently in progress. Clearly, better staging techniques would be highly desirable. Ultimately, we hope option 4 will succeed option I as preferred management, but that time has not yet arrived. Finally, we believe that success in the management of these patients is contingent upon the availability of experienced physicians of numerous disciplines. All patients should be treated by such individuals, and the rarity of this disease makes such referrals realistic.",
author = "Williams, {S. D.} and Lawrence Einhorn",
year = "1982",
language = "English",
volume = "66",
pages = "15--18",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Clinical stage I testis tumors

T2 - The medical oncologist's view

AU - Williams, S. D.

AU - Einhorn, Lawrence

PY - 1982

Y1 - 1982

N2 - We believe that 'standard' therapy for clinical stage I nonseminomatous testes germ cell tumors (NSGCT) patients continues to be extended bilateral retroperitoneal lymphadenectomy including suprahilar dissection (RPLND). This approach yields cure rates unparalleled in cancer treatment, with negligible treatment mortality and the avoidance of systemic therapy in most patients. Pathologic stage II patients are identified and managed accordingly, with RPLND being potentially curative in these patients. Excluding reproductive function, long-term complications are nearly zero after RPLND. Sterility is a problem but it has been overemphasized and may be reduced by relatively minor operative modification. Option 2 (radiation), we believe, might be reasonable for the rare patient who has unacceptably high operative risk, but long-term complications and a possible inferior therapeutic result make it much less desirable. Option 3 (chemotherapy only) exposes too many patients to systemic therapy and, we believe, has an unacceptable morbidity and mortality compared to option 1. Option 4 (observation) has for us a great deal of appeal for obvious reasons. However, its success is unknown in terms of likelihood of cure. It is not 'standard' therapy and should be offered only in the context of a prospective clinical trial, several of which are currently in progress. Clearly, better staging techniques would be highly desirable. Ultimately, we hope option 4 will succeed option I as preferred management, but that time has not yet arrived. Finally, we believe that success in the management of these patients is contingent upon the availability of experienced physicians of numerous disciplines. All patients should be treated by such individuals, and the rarity of this disease makes such referrals realistic.

AB - We believe that 'standard' therapy for clinical stage I nonseminomatous testes germ cell tumors (NSGCT) patients continues to be extended bilateral retroperitoneal lymphadenectomy including suprahilar dissection (RPLND). This approach yields cure rates unparalleled in cancer treatment, with negligible treatment mortality and the avoidance of systemic therapy in most patients. Pathologic stage II patients are identified and managed accordingly, with RPLND being potentially curative in these patients. Excluding reproductive function, long-term complications are nearly zero after RPLND. Sterility is a problem but it has been overemphasized and may be reduced by relatively minor operative modification. Option 2 (radiation), we believe, might be reasonable for the rare patient who has unacceptably high operative risk, but long-term complications and a possible inferior therapeutic result make it much less desirable. Option 3 (chemotherapy only) exposes too many patients to systemic therapy and, we believe, has an unacceptable morbidity and mortality compared to option 1. Option 4 (observation) has for us a great deal of appeal for obvious reasons. However, its success is unknown in terms of likelihood of cure. It is not 'standard' therapy and should be offered only in the context of a prospective clinical trial, several of which are currently in progress. Clearly, better staging techniques would be highly desirable. Ultimately, we hope option 4 will succeed option I as preferred management, but that time has not yet arrived. Finally, we believe that success in the management of these patients is contingent upon the availability of experienced physicians of numerous disciplines. All patients should be treated by such individuals, and the rarity of this disease makes such referrals realistic.

UR - http://www.scopus.com/inward/record.url?scp=0020082511&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020082511&partnerID=8YFLogxK

M3 - Article

VL - 66

SP - 15

EP - 18

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 1

ER -